Description

The NGLY1 Knockout HEK293T Cell Line is a human cell line engineered by CRISPR/Cas9-mediated disruption of the NGLY1 gene, providing a stable loss-of-function model for studying N-glycanase 1 in human embryonic kidney cells. The targeted disruption eliminates functional NGLY1 expression, creating a reliable tool for investigating cytosolic deglycosylation and protein quality control. As a cell line format, it supports diverse biochemical and cell-based assays.

The host HEK293T cell line is a widely used derivative of HEK293, constitutively expressing SV40 large T antigen for episomal plasmid replication, leading to high protein yield and viral production. These human embryonic kidney cells grow robustly and are highly transfectable, making them ideal for genetic manipulation. Their well-characterized secretory pathway and active proteostatic machinery are especially relevant for endoplasmic reticulum studies.

Mechanistically, NGLY1 encodes a cytosolic N-glycanase that cleaves N-linked glycans from misfolded glycoproteins retrotranslocated from the endoplasmic reticulum, a critical step in ER-associated degradation (ERAD). This deglycosylation facilitates proteasomal processing and generates free oligosaccharides. NGLY1 functions with p97/VCP, HRD1, and Derlin-1, and also collaborates with ENGase. Its activity is induced by ER stress downstream of the unfolded protein response (UPR). In the knockout line, impaired deglycosylation leads to misfolded glycoprotein accumulation and may activate ER stress sensors such as BiP, calnexin, and calreticulin, disrupting proteostasis.

In HEK293T cells, loss of NGLY1 profoundly alters glycoprotein processing and ERAD due to their high secretory activity. This knockout line provides a powerful system for dissecting how cytosolic glycan catabolism integrates with the ubiquitin-proteasome system and ER quality control machinery. It enables precise modeling of NGLY1 deficiency, a congenital disorder of deglycosylation associated with neurodevelopmental abnormalities, allowing researchers to delineate molecular pathology and compensatory mechanisms.

Applications span ERAD studies, protein quality control, and NGLY1 deficiency disease modeling. Researchers can perform Western blotting for glycoprotein accumulation, immunofluorescence for ER stress markers, and proteasome activity assays. RT-qPCR and RNA-seq enable transcriptomic profiling, while deglycosylation assays directly quantify N-glycan release. The model is excellent for high-throughput screening of proteostasis modulators and flow cytometry-based viability assessments under ER stress. For further technical information, contact Ascent Research.